Target Disease: Prostate Cancer

The Problem:

• Prostate Cancer is the most common cancer and the second leading cause of cancer death among men in the United States and worldwide
• Global incidence of prostate cancer is increasing in Asia, Northern and Western Europe with potential to increase further in future decades
• As people live longer, Prostate Cancer is a common and important disease creating significant burden to the healthcare system.
• $12 billion spent annually on the treatment of prostate cancer in the US alone

Facts:

• Screening with prostate-specific antigen (PSA) test and the digital rectal exam (DRE) does not provide a definite diagnosis of prostate cancer
• Prostate cancer often has no symptoms until the disease is advanced
• Prostate biopsy has a 30-40% false negative rate requiring stressful, repeat procedures

Opportunity:

• Early stage detection is critical when the chances of treatment success are high
• A multi-modal approach, incorporating Imaging, is widely accepted as optimal
• High interest in the use of Imaging in detecting and managing metastatic Prostate Cancer
• DACI serves as accessory, predictive “value add” to existing tools